◆ 会议时间：2023年12月6日至8日
◆ 会议地点：瑞士 日内瓦/Geneva, Switzerland

◆ 会议简介：

2023年ESMO免疫肿瘤学大会将于2023年12月6日至8日在瑞士日内瓦举行，会议由欧洲肿瘤内科学会（ESMO）组织。ESMO免疫肿瘤学大会是一个全球性会议，从免疫疗法的基础知识到最新的研究结果；从了解不同的治疗方案到毒性的管理和最新数据的解读，ESMO免疫肿瘤学大会将满足对癌症治疗这一热门领域感兴趣的肿瘤学利益相关者的不同需求。

欧洲肿瘤内科学会（ESMO）成立于1975年，是全球领先的肿瘤内科学专业组织。ESMO是肿瘤学教育和信息的参考学会，现在全球160多个国家和地区拥有超过25,000余名会员；ESMO致力于通过宣促进多学科的癌症护理，支持肿瘤学家的专业发展以及在全球倡导可持续的癌症护理，尽而为癌症患者提供最佳的护理。未经许可禁止复制摘录转载本站任何内容-国际医学会议网(lingyuint.com)

Organized by: European Society for Medical Oncology

The ESMO Immuno-Oncology Congress is a global meeting offering an advanced educational programme and the latest scientific developments in this promising field.

From the basics of immunotherapies to the latest research results; from understanding different treatment options to the management of toxicities and interpretation of new data, the ESMO Immuno-Oncology Congress will cater to the diverse needs of oncology stakeholders with an interest in this topical field of cancer treatment.

Take part in this unique meeting to learn, share your research and build invaluable collaborations with fellow experts.

摘要征文投稿：

Abstract submission deadlines

*A preliminary abstract indicating the data expected to be available by the LBA deadline must be submitted online by 26 September 2023 as an “intent to submit a late-breaking abstract”.

点此提交摘要>>>Submit Abstract>>>

ESMO I-O 2023 Abstract Regulations提交指南

Outcome notifications

Outcome notifications are expected to be made available to first authors and submitters by end-October 2023.

Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by mid-November 2023.

Information for presenters

Detailed instructions for the preparation of slide presentations and/or posters will be made available by end-October in the section “Information for Presenters”.

Abstract submission categories

• Biomarker development
• Cell therapy immune engineering
• Clinical practice
• Therapeutic development
• Tumour biology and tumour microenvironment
• Miscellaneous

Late-breaking abstracts

Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes.

Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 26 September 2023 will be considered for late-breaking status.

Trial in Progress abstracts

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Immuno-Oncology Congress 2023.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.

Presentation and publication of accepted abstracts

The ESMO Immuno-Oncology Congress 2023 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

• Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
• Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
• Poster – Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.

All accepted abstracts, including late-breaking abstracts, will be published online only in the ESMO Immuno-Oncology Congress 2023 Abstract Book, a supplement to the official ESMO journal, Immuno-Oncology and Technology (IOTECH).

Publication schedule for accepted abstracts 

Details regarding the publication of accepted abstracts are available here.

ESMO Merit Travel Grants

A limited number of Merit Travel Grants to the ESMO Immuno-Oncology Congress 2023 are available, upon application, to first authors under the age of 40 (forty) who submit abstracts considered deserving of recognition. Selection will be made by the ESMO Immuno-Oncology Congress 2023 Scientific Committee on a competitive basis from among the accepted abstracts.

注册费：

In-person participation includes:

• Participation in scientific and educational live sessions with the possibility to interact with the expert panel table
• Onsite networking opportunities with faculty and peers
• Entry to the Poster and e-Poster area
• Interaction with the industry partners in the trade exhibition
• Participation in the Industry Satellite Symposia
• Access to the Virtual Platform to view sessions missed on-demand
• Post-event resources
• Coffee breaks and lunches

Online participation includes:

• Access to the Virtual Platform, with live streaming of all sessions
• Possibility to interact through the chat live discussion
• Access to e-Posters
• Entry to the virtual exhibition
• Participation in the Industry Satellite Symposia
• Post-event resources

Registration fees and deadlines

Individual registration will remain open for the duration of the meeting. The ESMO Congress Secretariat must receive one completed registration per participant and the corresponding payment in EUR by the given deadlines.

ESMO membership must be active seven (7) days prior to the registration deadline for the reduced member registration fee to be applied. Please visit membership section to check eligibility criteria, benefits, and to complete the membership application.

* Applicable to ESMO members from developing countries only.

At the time of application, developing countries are defined by ESMO according to the World Bank classification of low, lower-middle and upper-middle countries based on the Gross National Income (GNI) per capita. Download the PDF outlining which countries are eligible for the discounted registration fees.

**ESMO Members must be under 40 and in training to qualify for this fee.

Webcasts

The Congress webcasts will be available for all delegates and will include all the sessions of the official programme where speaker permission is granted.

◆ 参会对象：：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。